Learn how your company can benefit from the advanced research tools at MAX IV and ESS in your drug development process – from early drug discovery to formulation.
Join a one-day seminar with presentations from MAX IV and ESS as well as companies that are taking advantage of the analytical techniques available at these research facilities. You will get an insight on how these tools create value and how they can help you in developing new drugs of tomorrow.
The day will be rounded off by a guided tour to the MAX IV laboratory. Register here
Moderator: Pia Kinhult - Strategic Advisor - ESS
Pia Kinhult - Strategic Advisor - ESS Stefan Johansson - Managing Director - Invest in Skåne Sindra Petersson Årsköld - Senior Advisor - ESS Tomas Lundqvist - Life Science Director - MAX IV Björn Walse - CEO - SARomics Biostructures Mathias Norrman - Principle Scientist - Novo Nordisk Anna Collén - Project Director Pharmaceutical Development - AstraZeneca
The Startup Challenge is a pitching competition giving innovative entrepreneurs an opportunity to showcase. Selected companies will present their innovative technologies to a selected jury representing life science executives from industry and finance.
Optimov (DEN) – Metabogen (SWE) – Bactavia (SWE) – Innovosens (SWE) – Sidekick Health (SWE) – Saga Diagnostics (SWE) – Neosense (SWE) – Adesante (FIN) – Cerenion (FIN) – Lipigon (SWE) – Immuneed (SWE) – Scandicure (SWE) – Edvince (SWE) – Finn Medicinen (SWE)
Rosemary Liu – Healthcare Solution Lead – Johnson & Johnson Innovation
Sandra Lindvall – Associate – Awapatent
Tomas Eriksson – CEO – A1M Pharma
09:30 Affilogic - Biotechnology - Other 09:37 Cline Scientific - Biotechnology - Other 09:49 Disruptive Materials - Biotechnology - Other 10:01 Axenis - Biotechnology - R&D Services 10:08 Bertin Pharma - Biotechnology - Therapeutics & Diagnostics 10:15 Cardiabase - Biotechnology - R&D Services 10:22 Neurotar - Biotechnology - R&D Services 10:34 BerGenBio - Biotechnology - Therapeutics & Diagnostics 10:41 Immunicun - Biotechnology - Therapeutics & Diagnostics
Hosted by: Lund University Diabetes CenterCo - Hosted by: LU Innovation, Novo Nordisk, Sanofi, Medeon
The diabetes session will focus on disruptive new solutions and future diabetes treatment options. Special focus will be on recent developments , where closed loop systems and ultrafast acting insulins will be game changers for insulin treated diabetes patients, especially those with unstable blood glucose.
Moderator: Karin Hehenberger - CEO and Founder - Lyfebulb
Søren Bregenholt - Corporate VP and Head of External Innovation - Novo Nordisk Charlotte Ling - Professor, Lund University Uli Wendt - Head External Innovation and Alliance Management, Global Diabetes Division, R&D - Sanofi Karin Hehenberger - CEO and Founder - Lyfebulb
11:15 Abera Bioscience - Biotechnology - Therapeutics & Diagnostics 11:22 Pelago Bioscience - Biotechnology - R&D Services 11:29 Double Bond Pharmaceutical - Pharmaceutical 11:35 Eurocine Vaccines - Biotechnology - Therapeutics & Diagnostics 11:42 Gradientech - Biotechnology - Therapeutics & Diagnostics 11:49 Scandinavian Biopharma - Biotechnology - Therapeutics & Diagnostics 11:56 Sinsa Lab - Biotechnology - Therapeutics & Diagnostics 12:03 Q-Linea - Biotechnology - Therapeutics & Diagnostics 12:10 NeoDynamics - HealthTech 12:17 Diamyd Medical - Biotechnology - Therapeutics & Diagnostics
This supersession will focus on a specific field of regenerative medicine, Gene Therapy. The possibility to replace defective genes in a patient’s cells with healthy ones using viral vectors and gene editing technologies, opens up the potential to treat or prevent numerous diseases which currently lack successful treatment. Although most gene therapies are still in an experimental stage, several examples have recently been successfully translated into clinical practice and products with regulatory approval. This session will discuss the diverse challenges involved in the translation of gene therapies to clinic and market, and highlight some successful examples.
Steffen Thirstrup - Director Regulatory Advisory Board - NDA Reg Benjamin Schmid - Research Scientist, Disease Models - Bioneer Sven Kili - Head of Cell & Gene Therapy Development - GSK Ralf Knöll - Chief Scientist - AstraZeneca
Anders Hjelmencrantz - Partner and European Patent Attorney - Zacco Ana Maria Henao Restrepo - Medical Officer, Department of Immunization Vaccines and Biologicals - WHO Guiseppe Ciaramella - Chief Scientific Officer - Moderna Valera Therapeutics Agnete Fredriksen - Chief Scientific Officer - Vaccibody AS
14:00 Biotrial Research - CRO/CMO 14:07 Clean Cells - CRO/CMO 14:14 PQE - Professional Services & Consulting 14:21 Amplexor - Professional Services & Consulting 14:28 RiverArk - Professional Services & Consulting 14:40 IntraVacc - Public & Non-Profit Organization 14:47 Rise Acreo - Public & Non-Profit Organizations 14:59 Asahi Kasei Bioprocess - Supplier & Engineering
Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed – resulting in decline of asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaboration with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. There are several potential advantages of this approach. But this session will also reflect upon questions like: What would be the primary driving forces for different parties to engage in this type of collaborations? Are there also complications with the phenomenon? How does the excess of promising assets with large biopharma companies affect other parts of the life science ecosystem?
Moderator: Ulrica Sehlstedt - Partner - Arthur D. Little
Jo Sawyer - Head of External Partnerships - Novartis Ben van der Schaaf - Principal - Arthur D. Little Ulrica Sehlstedt - Partner - Arthur D. Little Johan Christenson - Partner - HealthCap Birgitte Volck - Vice President, Head of R&D Rare Diseases - GSK
Many of the service providers in life science R&D have their own research. They provide much more than just an extra pair of hands and they spend high amounts on in house development of their services. With this super session, we will highlight their efforts and importance for the life science ecosystem where many of the companies are small and source for the latest technologies for their research and development.
Moderator: Christina Herder - CEO - Modus Therapeutics
Christina Herder - CEO - Modus Therapeutics Torkel Gren - Senior Sales Director, Development Services - Recipharm Sverre Bengtsson - CEO - Pharma Consulting Group Andy Gibbs - Drug Development Leader - Covance Michael Dabrowski - CEO - Pelago Bioscience
08:00 OxThera - Biotechnology - Therapeutics & Diagnostics 08:12 Spago Nanomedical - Biotechnology - Therapeutics & Diagnostics 08:24 Staten Serum Institut - Biotechnology - Therapeutics & Diagnostics 08:36 Stayble Therapeutics - Biotechnology - Therapeutics & Diagnostics 08:48 Thermo Fisher Scientific - Biotechnology - Therapeutics & Diagnostics 09:00 Wnt Research - Biotechnology - Therapeutics & Diagnostics
08:00 Targovax - Biotechnology - Therapeutics & Diagnostics 08:07 Acesion Pharma - Biotechnology - Therapeutics & Diagnostics 08:19 Hansa Medical - Biotechnology - Therapeutics & Diagnostics 08:31 Oncology Venture - Biotechnology - Therapeutics & Diagnostics 08:43 Ectin Research - Pharmaceutical 08:50 Klaria Pharma - Pharmaceutical 08:57 Redwood Pharma - Pharmaceutical 09:04 Vicore Pharma - Pharmaceutical
Research collaboration and funding opportunities for SMEs, Research Institutions, Hospitals and other stakeholders in the area of medicine development.
The Innovative Medicines Initiative (IMI2) is Europe’s largest public-private partnership in life science. It is jointly run and funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve the process of developing new drugs and treatments by supporting cooperation in research and development. IMI projects address such themes as preclinical and clinical methodological advancements, Digital Health, personalized medicine, Diabetes, Neurosciences and Oncology
The event is organized by VINNOVA , the Danish Agency for Science and Higher Education and The Research Council of Norway.
Who should join this session?
The workshop is an opportunity for a wide range of stakeholders – not least small and medium sized companies – to learn about the opportunities for R&D collaboration with the European pharmaceutical industry through IMI funded projects. The workshop will highlight the experiences and learnings of Swedish and Danish IMI project participants from both industry and academia.
Magda Chlebus - Director of Science Policy - EFPIA Magali Poinot - Advisor and Legal Manager - IMI Joint Undertaking Peter Olofsson - CEO - Redoxis AB Poul Henning Jensen - Professor - Dept. Of Biomedicine, Aarhus University
The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.
Moderator: Benedicte Bakke - Senior Advisor, International Healthcare - DNB
Benedicte Bakke - Senior Advisor, International Healthcare - DNB Khatereh Ahmadi - Executive Director, Oncology Search and Evaluation Lead - MSD Per Norlèn - CEO -Alligator Bioscience Stefan Ries - Global Head of External Innovation, Oncology Discovery - pRED Roche Christophe Bonny - CSO - Enterome Henrik Winther - Senior Vice President, Precision Diagnostics - Immunovia Richard Stratford - CEO - OncoImmunity Gary Sclar - Vice President - Dana-Farber Innovations
How can your company benefit from using MAX IV and ESS when developing new drug formulations?
The pharmaceutical industry will give examples on how they have used synchrotron and neutron light sources in drug formulation experiments and what potential they see with these facilities in the future.
Moderator: Anna Sandström - Director Science Relations - AstraZeneca
Anna Sandström - Director Science Relations - AstraZeneca Anna Collén - Project Director Pharmaceutical Development - AstraZeneca Mathias Norrman - Principle Scientist - Novo Nordisk
Moderator: Pontus Ottosson - Head of Investments - Chalmers Ventures
Pontus Ottosson - Head of Investments - Chalmers Ventures Anna Danestig - Key Account Manager - PRV Yilmaz Mahshid - Investment Manager Life Science - Industrifonden Stephan Christgau - Partner - Novo Seeds